-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1098 Estrogens and Prolactin Do Not Regulate Maternal and Embryo Iron Homeostasis during Pregnancy

Program: Oral and Poster Abstracts
Session: 102. Iron Homeostasis and Biology: Poster I
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Maternal Health
Saturday, December 9, 2023, 5:30 PM-7:30 PM

Veena Sangkhae, PhD, Vida Zhang, PhD*, Tomas Ganz, MD, PhD and Elizabeta Nemeth, PhD

Center for Iron Disorders, David Geffen School of Medicine at UCLA, Los Angeles, CA

Iron is essential for maternal and fetal health but the molecular mechanisms ensuring increased iron availability during pregnancy are not well understood. Hepcidin is the key iron-regulatory hormone and functions by blocking iron absorption, recycling and mobilization from stores, effectively decreasing plasma iron levels. In healthy human and rodent pregnancies, maternal hepcidin decreases starting in the second trimester and is nearly undetectable by late pregnancy. This decrease in hepcidin allows for greater iron availability for transfer to the fetus. If hepcidin is not appropriately suppressed during pregnancy, it results in fetal anemia, intrauterine growth restriction, and even fetal demise in severe cases1.

Unrelated to pregnancy, hormones estrogen and prolactin have been previously implicated in hepcidin regulation2,3, although with conflicting results on the direction of hepcidin change4-6. The levels of both hormones increase dramatically over the course of pregnancy, thus we hypothesized that they may modulate iron homeostasis during pregnancy. Studying the role of estrogens and prolactin during pregnancy is challenging as both hormones are required for pregnancy. Additionally, mice with global knockout (KO) of either estrogen receptor alpha or prolactin receptor are infertile. Thus, to determine the contribution of estrogens and prolactin on maternal hepcidin suppression during pregnancy, we generated liver-specific knockouts of either estrogen receptor alpha (Er-αf/f;Alb-Cre+) or prolactin receptor (Prlrf/f;Alb-Cre+), here abbreviated as ER-α KO and PRLR KO. Female ER-α KO, PRLR KO and WT mice were set up for timed pregnancy, and liver hepcidin mRNA, as well as maternal and embryo iron and hematological parameters were measured at E18.5 . Hepcidin suppression in ER-α KO and PRLR KO dams was not different from that in WT dams, suggesting that estrogens and prolactin are not major mediators of maternal hepcidin suppression. Additionally, maternal and embryo hematological parameters and liver iron concentrations were similar between WT, ER-α KO, PRLR KO pregnancies, further supporting our observation that estrogens and prolactin do not regulate iron homeostasis in pregnancy. The mechanisms by which maternal hepcidin is suppressed during pregnancy remain to be determined.

1Sangkhae V et al, Blood, 2020

2Yang Q et al, Endocrinology, 2012

3Wang J et al, Nanomedicine: nanotechnology, biology and medicine, 2015

4Zhen et al, Hepatology, 2013

5Ikeda Y et al, PloS one, 2012

6Lehtihet M et al, PloS one, 2016

Disclosures: Ganz: Intrinsic LifeSciences: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Silarus Therapeutics: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Ionis Pharmaceuticals: Consultancy; Disc Medicine: Consultancy. Nemeth: Disc Medicine: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Ionis Pharma: Consultancy; Protagonist Pharma: Consultancy; Intrinsic LifeSciences: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Vifor Pharma: Consultancy; Silarus Pharma: Consultancy, Current holder of stock options in a privately-held company; AstraZeneca and Fibrogen: Consultancy; Chiesi: Consultancy; Chugai: Consultancy; GSK: Consultancy; Novo Nordisk: Consultancy.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH